Novel therapeutic angiogenesis using mesenchymal stem cells from bone-marrow mononuclear cells and CD271+cells

本研究的目的是利用骨髓间充质干细胞(MSCs)开发新的治疗性血管生成。骨髓单个核细胞来源的MSCs和CD271细胞均表现出促血管生成的表型。促红细胞生成素预处理可增强MSCs的促血管生成特性。骨髓间充质干细胞是治疗性血管生成的有用细胞来源。骨髓间充质干细胞移植联合促红细胞生成素可能成为治疗外周动脉疾病血管生成的新策略。

The aim of this study was to develop novel therapeutic angiogenesis using mesenchymal stem cells(MSCs) from bone marrow. Both MSCs from total mononuclear cells and CD271+cells in bone marrow have shown pro-angiogenic phenotype. Preconditioning with erythropoietin enhanced the pro-angiogenic property in MSCs. MSC from bone marrow is useful cell source for therapeutic angiogenesis. MSC implantation combined with erythropoietin may become a new strategy for therapeutic angiogenesis in peripheral artery disease.